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ABSTRACT
BACKGROUND: Hypertension becomes increasingly prevalent after menopause.
Postmenopausal women are more responsive to salt than premenopausal women, and
they have been reported to develop marked renal vasoconstriction on a high-sodium
diet.
OBJECTIVE: The aim of this study was to assess whether angiotensin II receptor
blockade can restore a normal pattern of renal response to salt in postmenopausal
women on a high-sodium diet. We also assessed segmental renal sodium handling in
that population.
METHODS: Normotensive and hypertensive postmenopausal women not receiv-
ing hormone replacement therapy were enrolled in this prospective, double-blind,
placebo-controlled, crossover study. They were assigned to receive irbesartan 150 mg
or placebo for 6 weeks; the sequence in which they received irbesartan or placebo was
randomized. During the last week of treatment, they received a high-sodium diet
(250 mmol/d). Ambulatory blood pressure (ABP), glomerular filtration rate (GFR),
and effective renal plasma flow (ERPF) were measured using sinistrin and para-amino-
hippurate clearances. Renal sodium handling was assessed by measuring endogenous
lithium clearance on day 7 of the high-salt diet.
RESULTS: Nineteen women (mean age, 54.7 years; range, 43-72 years; 7 nor-
motensive subjects [mean age, 53.4 years; range, 47-61 years} and 12 hypertensive
subjects [mean age, 55.4 years; range, 43-72 years}) were included in the study.
When the data for all 19 subjects were pooled, ABP was significantly lower with
irbesartan than placebo both during the day (120 (3}/79 [2} vs 127 [3J/85 [2} mm Hg;
both, P < 0.01) and at night (systolic BP, 107 [4} vs 111 [4} mm Hg [P < 0.01} and
diastolic BP, 71 [2} vs 75 [2} mm Hg [P < 0.05}). Compared with placebo, irbesartan
was not associated with a significant change in GFR in either the normotensive or the
hypertensive women. When the data for all 19 subjects were pooled, irbesartan was
associated with a significant increase in ERPF compared with placebo (372 [21} vs
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324 [l8} mLlmin . 1.73 m 2; P < 0.05). When the hypertensive and normotensive
women were considered separately, the effect was more pronounced in the hyperten-
sive women than in the normotensive women, but the changes did not reach statistical
significance. When the data for all subjects were pooled, irbesartan was associated
with a significant increase in daytime utinary sodium excretion compared with pla-
cebo (135 [l3} vs 106 [l3} pmol/rnin; P < 0.05) and a significant decrease at night
(109 [l3} vs 136 [l9} prnol/rnin; P < 0.05). Fractional excretion oflithium (FEL) , an
inverse marker of proximal sodium reabsorption, increased significantly during the
daytime with irbesartan compared with placebo (47% (6.5%} vs 35% (4.7%}; P <
0.05). At nighttime, FELi was significantly higher in the hypertensive subjects receiv-
ing irbesartan compared with placebo (43% (7.2%} vs 29% (6.5%}; P < 0.05). The
fractional distal reabsorption of sodium did not change significantly with irbesartan
compared with placebo.
CONCLUSIONS: The results from this study suggest that angiotensin II receptor
blockade had a favorable impact on BP, renal hemodynamics, and renal sodium han-
dling in these salt-replete postmenopausal women. Blockade of the renin-angiotensin
system restored the normal pattern of renal response to high sodium intake in these
women. (Curr Ther Res Clin Exp. 2008;69:467-479) © 2008 Excerpta Medica Inc.
KEY WORDS: blood pressure, lithium, renal hemodynamics, gender, angiotensin II
receptor blockade.
INTRODUCTION
Cardiovascular disease is the leading cause of death in postmenopausal women.Iv'
Hypertension, a major cardiovascular risk factor, becomes more prevalent after meno-
pause. Hypertension is more prevalent in postmenopausal women than in age-matched
men.I Studies have reported that the renal response to stimuli, such as angiotensin II
or lower body negative pressure (a means to decrease the venous return to the heart),
that leads to activation of the sympathetic nervous system differs between men and
women, with a smaller augmentation of filtration fraction (FF) and a blunted increase
in intraglomerular pressure in women compared with men.4-6 The renal response to
salt among women has been reported to differ depending on whether they are in the
luteal or follicular phase of their menstrual cycle and whether they are taking contra-
ceptives or are in menopause.I"? In the luteal phase, the renal response to salt was
characterized by significant renal vasodilation and marked salt excretion from distal
nephrons compared to women during the follicular phase. We reported that after
menopause women receiving a high-salt diet had a significant increase in blood pres-
sure (BP), with increased proximal sodium reabsorption and marked and statistically
significant renal vasoconstriction.? These findings suggested that with the onset of
menopause, BP became salt-sensitive, a pattern that might be due to aging as well as
to modification of the sex hormone profile; these results have been confirmed. 10
The goal of the present study was to assess whether angiotensin II receptor block-
ade could restore a normal pattern of renal response to salt in postmenopausal women
on a high-sodium diet. The primary end point was to measure ambulatory BP (ABP)
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and renal hemodynamic changes induced by an angiotensin receptor blocker (ARB) in
salt-replete postmenopausal women. The secondary end point was to assess segmental
renal sodium handling in that population.
SUBJECTS AND METHODS
SUBJECTS
This was a prospective, double-blind, randomized, placebo-controlled, crossover
study (Figure). The study included postmenopausal volunteers recruited among out-
patients of University Hospital (Geneva, Switzerland) who were not receiving hor-
mone replacement therapy (HRT). The participants were recruited using placards
posted in the hospital that described the study, The women were classified as hyper-
tensive (office BP ~140/90 mm Hg and/or mean 24-hour ABP monitoring {ABPM]
~125/80mm Hg) or normotensive (office BP <140/90 mm Hg and/or mean 24-hour
ABPM < 125/80 mm Hg). All the women underwent natural menopause, defined as
~1 year since their last menstruation. All were required to be nonsmokers and none
could be taking antihypertensive drugs or any medication known to affect BP or renal
function. Exclusion criteria were any cardiac or renal disease, diabetes, anemia, and use
of aspirin, NSAIDs, or HRT.
At the initial visit, the subjects gave a full medical history (verified through medi-
cal records) and underwent a clinical examination. They were randomly assigned to
receive either placebo or the ARB irbesartan 150 mg QD for 6 weeks, according to
the crossover design. There was a 2-week washout period between the drug and pla-
cebo phases. Randomization of the sequence of placebo and active treatment periods
was performed by a pharmacist who had no contact with the subjects or the clinicians.
The random allocation scheme used a computer-generated random number list. The
placebo and the active treatment, which were prepared by a pharmacist, were identical
in appearance and were dispensed in identical bottles. The subjects received compen-
sation for travel and meals. The clinicians were compensated for laboratory tests,
ABPM devices, nurses' salaries, and travel to a medical congress. The study protocol
was reviewed and approved by the institutional ethics committee (University Hospi-
tal) and all subjects provided written informed consent.
Tolerability to treatment was assessed at each visit by subject interview. The sub-
jects were specifically asked if they had been suffering from fatigue, dizziness, or feel-
ings of fainting when standing up.
CLINICAL INVESTIGATION
During the last week of therapy (week 6 ofeach treatment phase), subjects received
a high-salt diet, which was achieved by adding 6 g/d of sodium chloride to their usual
diet. On day 7 of both diet periods, 24-hour urine was collected separately during the
day (8:00 AM-1O:00 PM)and the night (10:00 PM-8:00 AM) to measure sodium excre-
tion. Concomitantly, 24-hour BP was recorded using ABPM (Diasys, Physicor, Ge-
neva, Switzerland). This device was validated by the British Hypertension Society and
was rated B/B.ll ABP was measured at 20-minute intervals during the day and every
60 minutes at night. The next day, patients were admitted to the hospital at 8:30 AM
469
~'"o
Randomization to irbesartan 150 mg or placebo Crossover to irbesartan 150 rng or placebo
ABPM, U24
Renal function study
ABPM, U24
Renal function study
n
c
:II
:II
111
Z
-I
-I
:z:
111
:II
l>
"111
C
-I
n
:ll
111
III
111
l>
:II
n
:z:
4-Week washout 6-Week treatment 2-Week washout
High-salt diet
f------j
6-Week treatment
High-salt diet
f------j
Figure. Study design. ABPM =24-hour ambulatory blood pressure monitoring; U24 =24-hour urine collection.
A. PECHERE-BERTSCHI ET AL.
after an overnight fast to have their renal function measured. Renal hemodynamics
were measured using sinistrin (an analogue of inulin) and para-amino-hippurate
(PAH) clearances, as described previously.V After lying quietly for a 90-minure
equilibration period in the supine position and administration of an oral water load
of 5 mL/kg to ensure stable urine output, glomerular filtration rate (GFR) and effec-
tive renal plasma flow (ERPF) were measured once in each of the two 90-minure
clearance intervals.
ANALYTIC PROCEDURES
Sodium excretion was expressed as UNa' V in mmolld or prnol/min, where UNa was
the urinary sodium concentration and V was the urine volume expressed either in
mL/24 hours or in mL/min. The FF was determined by dividing the GFR by effective
renal plasma flow. Renal vascular resistance was calculated as follows:
MBPI(RBFl[l-Ht]),
where MBP was mean BP, RBF was renal blood flow, and HI was hematocrit. Proxi-
mal renal sodium handling was assessed by measuring endogenous lithium in plasma
and urine, as described previously, 12,13 and by the fractional excretion oflithium (FELi )
and sodium (FEN) using the standard formula (FEx = X clearance/GFR). The frac-
tional distal reabsorption of sodium (ie, the percentage of the distally delivered sodi-
um reabsorbed in the postproximal nephron segments) was calculated as follows:
Sinistrin" and PAHt were purchased directly from the manufacturers.
STATISTICAL ANALYSIS
All results were expressed as mean (SEM). Data were analyzed using a paired or
unpaired I test for independent samples, when appropriate . The primary analysis was
based on data from the per-protocol population. A modified intention-to-treat analy-
sis was also performed and lead to the same results . The main comparison was made
between placebo and irbesartan, with each subject being her own control. We calcu-
lated that 18 women would be needed to demonstrate a 10% difference in BP and
FELi and a 20% change in ERPF, with an ex of 0.05 and a 13 of 0.20.
RESULTS
We assessed 20 women for participation in the srudy. One of them successfully com-
pleted the screening, but withdrew prior to any srudy procedures. Therefore, the
study included 19 postmenopausal white volunteers (mean age, 54.7 years; range,
43-72 years): 7 normotensive subjects (mean age, 53.4 years; range, 47-61 years) and
*Trademark: Inuresr'" (Laevosan Gesellschafr, ZUrich, Switzerl and ).
t Manufactered by SERB Laboraroires Pharmaceutiques, Pari s, France.
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Table I. Baseline demographic and clinical characteristics of postmenopausal women
enrolled in the study (N =19). Data are mean (SEM) unless noted otherwise.
All Normotensive Hypertensive
Characteristic (N = 19) (n = 7) (n = 12)
Age, y 54.7 (4.2) 53.4 (3.8) 55.4 (4.1)
Range 43-72 47-61 43-72
Weight, kg 68.9 (2.5) 65.6 (2.5) 70.8 (3.7)
BMI, kg/m2 25.9 (1.1) 24.3 (1.1) 26.8 (1.6)
Office BP, mm Hg 128 (4.1)/85 (4.4) 116 (3.1)/80 (3.4) 152 (6.0)/96 (4.2)*
Serum creatinine, urnot/L 68.3 (2.2) 69.2 (3.8) 67.8 (2.7)
FSH, U/L 50.2 (7.3) 58.3 (13.5) 45.4 (8.7)
Plasma estradiol, pg/mt, 20.9 (6.4) 24.3 (15.7) 18.9 (5.1)
BMI =body mass index; BP =blood pressure; FSH = follicle-stimulating hormone.
*p < 0.05 versus normotensive subjects.
12 hypertensive subjects (mean age, 55.4 years; range, 43-72 years) (Table I). There
were no statistically significant differences between the normotensive and the hyperten-
sive women, except for baseline BP (116 [3.1)/80 [3.4J vs 152 [6.0J/96 [4.2J mm Hg;
both, P < 0.05). No subjects were lost to follow-up.
BLOOD PRESSURE AND HEART RATE RESPONSES TO ANGIOTENSIN II
RECEPTOR BLOCKADE
Daytime and nighttime ABPs and heart rates are presented in Table II. When the
data for all 19 subjects were pooled, ABP was significantly lower with irbesartan than
placebo both during the day (systolic BP, 120 [3J vs 127 [3J mm Hg; diastolic BP,
79 [2J vs 85 [2J mm Hg; both, P < 0.01) and at night (systolic BP, 107 [4J vs
111 [4J mm Hg; diastolic BP, 71 [2J vs 75 [2J mm Hg; P < 0.01 and P < 0.05, re-
spectively). The effect of irbesartan on BP was observed essentially in the hypertensive
women. A nocturnal physiologic decrease in systolic and diastolic BP was observed
during both placebo and irbesartan treatment (P < 0.01, nighttime vs daytime).
No significant effect was observed on heart rate.
RENAL HEMODYNAMIC RESPONSE TO ANGIOTENSIN II RECEPTOR BLOCKADE
The effects of irbesartan 150 mg on renal hemodynamics are presented in Table III.
Compared with placebo, irbesartan was not associated with a significant change in
GFR in either the normotensive or the hypertensive women. When the data for the
19 subjects were pooled, irbesartan was associated with a significant increase in ERPF
compared with placebo (372 [Zl ] vs 324 [I8J mLimin . 1.73 m 2; P < 0.05). When
the hypertensive and normotensive women were considered separately, the effect was
more pronounced in the hypertensive subjects than in the normotensive subjects, but
the changes did not reach statistical significance. FF was numerically lower with irbe-
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Table II. Ambulatory blood pressure (BP) and heart rate responses to angiotensin II
receptor blockade with Irbesartan 150 mg/d compared with placebo In salt-
replete postmenopausal women. Data are mean (SEM).
All Normotensive Hypertensive
Variable/Group (N = 19) (n = 7) (n =12)
Dayt ime systolic BP, mm Hg
Irbesartan .150 rng .120 (3)* 110 (4) 125 (3)t
Placebo 127 (3) 114 (4) 13 5 (4)
Daytime diastolic BP, mm Hg
Irbesartan 150 rng 79 (2)* 75 (2)t 82 (2)*
Placebo 85 (2) 81 (3) 88 (2)
Nighttime systolic BP, mm Hg
Irbesartan 150 mg 107 (4)* 95 (4) 115 (5)
Placebo 1.1.1 (4) 98 (7) .119 (5)
Nighttime diastolic BP, mm Hg
Irbesartan .150 mg 71 (2)t 68 (2) 73 (2)t
Placebo 75 (2) 69 (4) 78 (2)
24· Hour heart rate , beats/ min
Irbesartan .150 rng 82 (2) 85 (3) 80 (2)
Placebo 81 (2) 82 (3) 8.1 (3)
*p < 0 .01 versus placebo.
t p < 0.05 versus placebo .
sartan than placebo, but the diffe rence d id not reach statistical sig nificance. Renal
vascular resistance were significantly lower in women receiving irbesarta n than pla-
cebo, assessing a renal vasodilation.
RENAL TUBULAR RESPONSE TO ANGIOTENSIN II RECEPTOR BLOCKADE
Consumption of a high-sodium diet was associated with a significant in crease in
body weight in women receiving placebo and irbesartan (1.0 1 [O.34} and 0.89 [O.31} kg ,
respectively; both, P = 0 .005 vs baseline).
Table IV shows the U Na ' V and the FELi with placebo and irbesartan. W hen the
data for all subjects were pooled, daytime U Na' V was associated with a sig nificant
increase with irbesartan compared with placebo 035 [l 3} vs 106 [l3} prnol/rn in ; P <
0.05) and a sig nificant decrease during th e night (109 [l3} vs 136 [l9} prnol/rn in ;
P < 0 .05), sugge st ing a change in the 24-hout d istribution of sodium excretion.
Twenty-four hour sodium balance remained consta nt in both phases.
W hen the data for all 19 subjects were pooled , FELi, an inverse marker of proximal
sodium reabsorption, increased sig nificantly dur ing the daytime wi th irbesa rtan com-
pared wi th placebo (47 % [6.5%} vs 35% [4 .7%}; P < 0 .0 5). At nighttime, FELi was
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Table III. Renal hemodynamic response to angiotensin II receptor blockade with irbe-
sartan 150 mg compared with placebo in salt-replete postmenopausal women.
Data are mean (SEM).
All Normotensive Hypertensive
Variable/Group (N = 19) (n = 7) (n = 12)
GFR, rnl.zmln . 1.73 m2
Irbesartan 150 mg 60 (3.3) 58 (6.0) 62 (3.4)
Placebo 60 (2.4) 55 (4.3) 62 (2.6)
ERPF, mL/min . 1.73 m2
Irbesartan 150 mg 372 (21)* 349 (25) 383 (31)
Placebo 324 (18) 315 (27) 329 (25)
FF, %
Irbesartan 150 rng 17.0 (0.1) 17.1 (1.6) 17.1 (1.3)
Placebo 20.0 (0.2) 17.8 (0.6) 20.6 (2.3)
RVR, dyne/ern-
Irbesartan 150 mg 12,148 (742)* 11,588 (725) 12,476 (1110)
Placebo 14,972 (1118) 13,720 (1092) 15,702 (1652)
GFR '" glomerular filtration rate; ERPF", effective renal plasma flow; FF'" filtration fraction; RVR '" renal
vascular resistance.
*p < 0.05 versus placebo.
significantly higher in the hypertensive subjects receiving irbesartan compared with
placebo (43% [7.2%} vs 29% [6.5%}; P < 0.05). The fractional distal reabsorption of
sodium did not change significantly with irbesartan compared with placebo.
DISCUSSION
Taken together, the results of the present study suggest that even on a high-sodium
diet, an ARB administered to these postmenopausal women lowered 24-hour ABP,
induced renal vasodilation with no change in GFR, and significantly reduced proxi-
mal sodium reabsorption. The effects on BP and proximal renal segmental reabsorp-
tion were observed mainly in the hypertensive women and to a lesser degree in the
normotensive women. These findings suggest that ARB therapy in postmenopausal
women restored the normal pattern of renal response to salt that was previously de-
scribed in premenopausal women."
All of the mechanisms responsible for the increase in BP after menopause have not
been identified. The increased incidence of hypertension observed in postmenopausal
women might be related to several mechanisms, including sodium retention or an
altered BP response to sodium. We previously reported that the BP of menopausal
women became salt-sensitive and that postmenopausal women respond to a high-salt
diet with marked renal vasoconstriction, whereas in younger premenopausal women,
a salt load-induced renal vasodilation.?
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Table IV. Segmental renal sodium handling in salt-replete postmenopausal women dur-
ing angiotensin " receptor blockade with Irbesartan 150 mg compared with
placebo. Data are mean (SEM).
All Normotensive Hypertensive
Variable/Group (N = 19) (n = 7) (n = 12)
Daytime UNa· V. umol/min
Irbesartan 150 rng 135 (13)* 126 (17)* 142 (19)
Placebo 106 (13) 90 (13) 115 (19)
Nighttime UNa· V. urnol/rnln
Irbesartan 150 mg 109 (13)* 122 (19) 101 (17)
Placebo 136 (19) 151 (34) 127 (23)
Daytime FEu. %
Irbesartan 150 mg 47 (6.5)* 45 (2.0) 39 (4.6)
Placebo 35 (4.7) 41 (5.5) 32 (6.5)
Nighttime FEu. %
Irbesartan 150 rng 46 (6.1) 50 (1.2) 43 (7.2)*
Placebo 38 (5.4) 56 (5.5) 29 (6.5)
Daytime FDRNa• %
Irbesartan 150 mg 98 (1.0) 98 (0.4) 97 (0.6)
Placebo 97 (0.4) 98 (0.3) 98 (1.0)
Nighttime FORNa• %
Irbesartan 150 rng 98 (0.4) 98 (0.3) 98 (0.5)
Placebo 96 (1.8) 98 (0.6) 94 (2 .0)
UNa = urinary sodium concentration; V = urine volume; FEu = fractional excretion of lithium; FORNa =
fractional distal reabsorption of sodium.
•p < 0.05 versus placebo.
An increase in body weight occurring at menopause that may be linked co the
change in sodium sensitivity in women has also been associated with a significant
increase in ABp'9 In this study, despite a high-salt diet, which was associated with an
increase in body weight and has been reported to blunt the antihypertensive effect of
blockers of the renin-angiotensin systern.l" irbesartan was associated with a signifi-
cant decrease in BP. This effect was more pronounced in hypertensive subjects, sug-
gesting that blockade of the renin system limited the salt-induced renal alterations
that occurred in these postmenopausal women and restored BP salt sensitivity. Irbe-
sartan has also been reported to reverse the nondipper BP profile, that is, the absence
of the physiological decrease of BP during nighttime, in salt-sensitive hypertensive
patients on a high-salt diet .15 In our subjects, irbesartan was not associated with a
change in the dipping profile ofBP bur was associated with a change in the day-night
distribution of UNa. Therefore, blockade of the renin-angiotensin system during
menopause may be one way to restore BP salt sensitivity.
475
CURRENT THERAPEUTIC RESEARCH
Before menopause, women might be protected against salt-sensitive hypertension
by female sex hormones, which affect renal sodium excretion. 16Changes in estrogen!
androgen ratios at menopause could thus playa role in triggering elevated Bp'16 The
possibility that androgens are important in the development of arterial hypertension
in women should also be considered. Some data support this hypothesis, as male sex
hormones contribute to the exacerbation of hypertension in animal models of spon-
taneously hypertensive rats (SHRs) by reducing the pressure-natriuresis curve. 17
The androgen-promoted exacerbation of BP appears to be mediated by the renin-
angiotensin system.3,I S
At menopause, the decrease in female sex hormones may also influence renal func-
tion. As discussed previously, a high-salt diet consumed for 1 week by menopausal
women led to renal vasoconstriction, with a decrease in effective renal plasma flow and
an increase in FF.9 This renal response contrasts with the one observed in younger,
premenopausal wornen.U? suggesting again that endogenous female sex hormones
playa role in mediating these alterations. In an animal model of postmenopausal hy-
pertension in SHRs, along with the increase in BP observed in older rats, rats also had
decreased GFR and renal plasma flow and increased renal vascular resistance compared
with young fernales.f" In these animals, blockade of the renin-angiorensin system re-
sulted in marked attenuation of glomerular injury, a decrease in microalbuminuria,
and reversal of renal hemodynamic changes. IS At menopause, activation of the renin-
angiotensin system might contribute to renal alterations independent of sodium in-
take. 2l,22 Our findings in postmenopausal women are consistent with these experi-
mental findings in animals, as angiotensin II receptor blockade restored the renal
hemodynamic response to salt.
Data on the changes in renal sodium handling induced by menopause are scarce. In
animal models, female sex hormones have been reported to protect against the devel-
opment of Dahl hypertension mediated by increases in dietary sodium.23 In some
models of ovariectomized rats fed a high-sodium diet, hypertension developed, but
reinstatement of a sodium chloride-deficient diet did not reverse the hyperrension.I''
suggesting that removal of the female hormones predisposed the animals to hyperten-
sion that was initially sodium-dependent but might become sodium-independent
with time. Androgens have been reported to increase tubular sodium and water
reabsorption and to activate various vasoconstrictor systems in the kidney, including
the renin-angiotensin and endothelin systems. Activation of these systems may lead
to increased sodium reabsorption in the proximal and distal tubules. Moreover, experi-
mental data suggest that androgens may directly upregulate the reabsorptive capacity
of the renal proximal tubule and increase the volume reabsorptive rate, thereby en-
hancing extracellular volume and BP.25 In our study, irbesartan decreased proximal
sodium reabsorption in both normotensive and hypertensive postmenopausal women.
With placebo as well as irbesartan, proximal sodium reabsorption was numerically
higher in the hypertensive women than in the normotensive women, as indicated by
a lower FELi . This was consistent with our initial observations in men suggesting that
essential hypertension was associated with increased reabsorption of sodium in the
proximal tubule, particularly on a high-salt diet.26,27 The impaired ability of the
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proximal tubule to regulate sodium excretion has also been associated with increased
BP salt sensitiviry.F" The natriuretic response to irbesartan is probably due to block-
ade of the tubular effects of angiotensin II, which is known to act specifically at that
segment of the nephron by promoting antinatriuresis. We reported that irbesartan,
even at lower doses of75 mg/d, increased UNa in normotensive men. 28
This observation may be of importance for the management of hypertensive post-
menopausal women in order to provide them with the best prevention of cardiovascular
and renal complications of hypertension. As there might be substantial gender-specific
differences in the ABP response to antihypertensive trearrnentsv'? studies specifically
designed to examine the gender aspect of preventing cardiovascular complications of
hypertension with blockers of the renin-angiotensin system should be performed.
LIMITATIONS
To detect the effect of salt loading, we should have compared active treatment and
placebo, not only on a high-salt diet, but also on a low-salt diet. The sample size used
in this study may appear small; however, because each woman received active treat-
ment and placebo (each being her own control), the statistical power of the study was
calculated to be sufficient to detect a difference. Adherence to treatment and to the
high-sodium diet was not monitored. Nevertheless, the statistical difference between
the 2 treatments gives an indirect validation of our findings.
CONCLUSIONS
The results of this study suggest that angiotensin II receptor blockade had a favorable
impact on BP, renal hemodynamics, and renal sodium handling in these salt-replete
postmenopausal women. Blockade of the renin-angiotensin system restored the nor-
mal pattern of renal response to high sodium intake in these women.
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